It may have taken a couple of years, but Exosome Diagnostics has finally raised the money it said it wanted to potentially launch its liquid biopsy-based diagnostic test.
Exosome announced today it has closed a $60 million Series B round of funding, money that it is putting toward getting its first oncology products on the market, expanding its diagnostics and regulatory divisions, and funding research into diagnostic tests for more diseases.
The wealth management industry has been facing a number of profound challenges after the financial crisis, making it difficult to serve the needs of HNWIs. A combination of structural and cyclical headwinds has put significant pressure on revenues, margins, and costs, leading to the emergence of trends aimed at augmenting revenues and controlling costs. This document provides a high-level analysis of the top 10 wealth management trends that are expected to impact the wealth management industry in 2016.
There are a slew of gene therapy companies trying to develop a long-lasting, perhaps even permanent treatment for hemophilia. The proof that these companies can really make an impact on the disease will come out in dribs and drabs from clinical trials over the next several years, and today, one of them, Dutch firm UniQure, did so with some promising early results.
This year has so far shaped up to be a breakout year for healthcare investing, with over $6B invested and deep-pocketed hedge funds and mutual funds increasingly involved in deals.
Pharmaceutical corporations are also playing a huge role in this space, with many pharma companies effectively outsourcing the R&D of some newer and experimental drugs to smaller, more nimble companies by investing in them.
In industrialized countries, a particularly high number of people suffer from arteriosclerosis -- with fatal consequences: Deposits in the arteries lead to strokes and heart attacks. A team of researchers under the leadership of the University of Bonn has now developed a method for guiding replacement cells to diseased vascular segments using nanoparticles. The scientists demonstrated in mice that the fresh cells actually exert their curative effect in these segments. However, much research remains to be done prior to use in humans. The results are now being published in the journal ACS NANO.
Quartzy, a lab supplies marketplace, announced it has closed a $17 million round in Series B financing to help the startup build up the supply of lab equipment offered to customers.
The startup launched out of Y Combinator four years back and has since partnered with several academic institutions, including Stanford to offer an alternative marketplace for pricier lab supplies. Quartzy does so with a bidding platform to help scientists find less expensive products from competing suppliers.
In recent years, a number of drug companies have zeroed in on a protein called myostatin, which can limit muscle growth and even cause them to waste away in certain diseases. A startup called Scholar Rock is now part of that group, and the Cambridge, MA-based company said today it has raised the cash needed to advance its own muscle-protecting drug into clinical trials.
When American troops are injured in the field, the first piece of life-saving medical equipment they may come into contact with nowadays is an Israeli-invented mini-sized manual ventilator. And not just American soldiers on the battlefield; the Pocket BVM has been used to treat thousands of people at the scene of numerous natural disasters, like in the huge earthquake that devastated Nepal earlier this year.
As we look back on the medtech developments of 2015 there’s definitely a sense that we’re living through revolutionary times. Nearly every day exciting and fascinating technologies are being unveiled by small and large companies, universities, and even tiny independent groups. Empowered by high-powered computers, 3D printers, and other technologies, researchers, scientists, and engineers are coming up with novel solutions to age-old medical problems. Everything from treating gunshot wounds to how fetuses inside the womb are monitored is going through change thanks to technologies developed by thousands of independent minds around the world.
Dentsu Ventures, the corporate venture capital of Japanese ad agency Dentsu, announced today that it has invested an undisclosed sum in San Diego-based Cue, the startup developing a health tracking device under the same name. Financial details have not been disclosed. For Dentsu Ventures, this is the fifth investment in a startup followed by Jibo (communication robot), Agolo (curated content generation), Nextbit (cloud-based smartphone), Sensai (big data analysis), and others.
